Tredje AP fonden Has $553,000 Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Tredje AP fonden trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 50.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,684 shares of the medical research company’s stock after selling 1,683 shares during the quarter. Tredje AP fonden’s holdings in Bio-Rad Laboratories were worth $553,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BIO. Principal Financial Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after purchasing an additional 21,669 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Bio-Rad Laboratories by 84.8% during the third quarter. Assetmark Inc. now owns 305 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 140 shares in the last quarter. Atria Investments Inc boosted its stake in shares of Bio-Rad Laboratories by 9.2% during the third quarter. Atria Investments Inc now owns 2,645 shares of the medical research company’s stock valued at $885,000 after purchasing an additional 223 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Bio-Rad Laboratories by 0.9% during the third quarter. Victory Capital Management Inc. now owns 21,294 shares of the medical research company’s stock valued at $7,125,000 after purchasing an additional 186 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Bio-Rad Laboratories by 82.6% during the third quarter. KBC Group NV now owns 3,095 shares of the medical research company’s stock worth $1,036,000 after acquiring an additional 1,400 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BIO. Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $255.34 on Friday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a twelve month low of $244.00 and a twelve month high of $387.99. The stock’s 50 day moving average is $311.97 and its 200-day moving average is $328.01. The firm has a market capitalization of $7.15 billion, a price-to-earnings ratio of -3.93 and a beta of 0.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.